The effect of oxytocin and Kisspeptin-10 in ovary and uterus of ischemia-reperfusion injured rats.

Aslan M, Erkanli Senturk G, Akkaya H, Sahin S, Yılmaz B

Taiwanese journal of obstetrics & gynecology1 Aug 2017Cited by 32 (Europe PMC)

PMID28805600DOI10.1016/j.tjog.2016.12.018PepBankPUB-28805600

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with ovarian and uterine ischemia-reperfusion injury, adding kisspeptin to oxytocin made no significant difference compared with oxytocin alone.
In plain wordsIn rats with ovarian and uterine injury, adding kisspeptin to oxytocin did not change the result compared with oxytocin alone.
Peptide
Kisspeptin-10
Outcome
No significant changeHistologic damage, oxytocin versus oxytocin plus kisspeptin
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion injury
Comparator
Oxytocin alone
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
There is no significant difference between OXY and OXY + Kisspeptin injected I/R groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
Report a problemFND-2880560002
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion injury, malondialdehyde levels were lower with kisspeptin and/or oxytocin than in the untreated injury group.
In plain wordsIn rats with injury, kisspeptin and/or oxytocin lowered a marker of oxidative damage compared with no treatment.
Peptide
Kisspeptin-10
Outcome
DecreaseMalondialdehyde level
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion injury
Comparator
Ischemia-reperfusion group
Outcome group
Oxidative stress · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
MDA levels were decreased in Kisspeptin and/or Oxytocin applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
Report a problemFND-2880560003
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion injury, SOD activity was higher with kisspeptin and/or oxytocin than in the untreated injury group.
In plain wordsIn rats with injury, kisspeptin and/or oxytocin raised an antioxidant enzyme compared with no treatment.
Peptide
Kisspeptin-10
Outcome
IncreaseSuperoxide dismutase activity
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion injury
Comparator
Ischemia-reperfusion group
Outcome group
Oxidative stress · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
SOD activity and GSH levels were increased in Kisspeptin and/or OXY applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
Report a problemFND-2880560004
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion injury, GSH levels were higher with kisspeptin and/or oxytocin than in the untreated injury group.
In plain wordsIn rats with injury, kisspeptin and/or oxytocin raised an antioxidant molecule compared with no treatment.
Peptide
Kisspeptin-10
Outcome
IncreaseGlutathione level
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion injury
Comparator
Ischemia-reperfusion group
Outcome group
Oxidative stress · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
SOD activity and GSH levels were increased in Kisspeptin and/or OXY applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
Report a problemFND-2880560005

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

05AnimalNot a test of Kisspeptin-10 aloneAnimal study (in vivo)Efficacy outcome
In rats with ovarian and uterine ischemia-reperfusion injury, cellular damage was reduced in the oxytocin and kisspeptin treated group compared with the kisspeptin-only and untreated injury groups.
In plain wordsIn rats with ovarian and uterine injury, oxytocin plus kisspeptin reduced cell damage compared with kisspeptin alone and with no treatment.
Peptide
Kisspeptin-10
Outcome
DecreaseOvary and uterus histologic damage with oxytocin and kisspeptin
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion injury
Comparator
I/R group and kisspeptin-only I/R group
Outcome group
Organ injury · Reproductive and sexual health
Source sentences
Summary
The cellular damage of ovary and uterus were reduced in OXY and Kisspeptin administered I/R group when compared to only Kisspeptin injected I/R group and I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-2880560001
06AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism
In rats with ovarian and uterine ischemia-reperfusion injury, malondialdehyde levels were lower in groups pretreated with kisspeptin, oxytocin or both than in untreated I/R.
In plain wordsIn rats with ovary and uterus injury, pretreatment with kisspeptin, oxytocin or both lowered a marker of cell damage compared with no treatment.
Peptide
Oxytocin
Outcome
DecreaseMalondialdehyde level in ovary and uterus
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion (I/R) injury
Comparator
I/R group without treatment
Outcome group
Oxidative stress · Reproductive and sexual health
Source sentences
Summary
MDA levels were decreased in Kisspeptin and/or Oxytocin applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2880560006
07AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism
In rats with ovarian and uterine ischemia-reperfusion injury, superoxide dismutase activity was higher in groups pretreated with kisspeptin, oxytocin or both than in untreated I/R.
In plain wordsIn rats with ovary and uterus injury, pretreatment with kisspeptin, oxytocin or both raised an antioxidant enzyme compared with no treatment.
Peptide
Oxytocin
Outcome
IncreaseSuperoxide dismutase activity in ovary and uterus
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion (I/R) injury
Comparator
I/R group without treatment
Outcome group
Oxidative stress · Reproductive and sexual health
Source sentences
Summary
SOD activity and GSH levels were increased in Kisspeptin and/or OXY applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2880560007
08AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism
In rats with ovarian and uterine ischemia-reperfusion injury, glutathione levels were higher in groups pretreated with kisspeptin, oxytocin or both than in untreated I/R.
In plain wordsIn rats with ovary and uterus injury, pretreatment with kisspeptin, oxytocin or both raised an antioxidant compound compared with no treatment.
Peptide
Oxytocin
Outcome
IncreaseGlutathione level in ovary and uterus
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion (I/R) injury
Comparator
I/R group without treatment
Outcome group
Oxidative stress · Reproductive and sexual health
Source sentences
Summary
SOD activity and GSH levels were increased in Kisspeptin and/or OXY applied I/R group compared to I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2880560008
09AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In rats with ovarian and uterine ischemia-reperfusion injury, cellular damage was reduced in the oxytocin and kisspeptin treated group versus kisspeptin alone and untreated I/R.
In plain wordsIn rats with ovary and uterus injury, oxytocin plus kisspeptin reduced tissue cell damage compared with kisspeptin alone and with no treatment.
Peptide
Oxytocin
Outcome
DecreaseHistopathologic cellular damage with oxytocin plus kisspeptin
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion (I/R) injury
Comparator
Kisspeptin alone and I/R group
Outcome group
Organ injury · Reproductive and sexual health
Source sentences
Summary
The cellular damage of ovary and uterus were reduced in OXY and Kisspeptin administered I/R group when compared to only Kisspeptin injected I/R group and I/R group.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2880560009
10AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In rats with ovarian and uterine ischemia-reperfusion injury, oxytocin alone and oxytocin plus kisspeptin did not differ significantly in cellular damage.
In plain wordsIn rats with ovary and uterus injury, oxytocin alone and oxytocin plus kisspeptin protected the tissue about equally.
Peptide
Oxytocin
Outcome
No significant changeCellular damage, oxytocin alone versus oxytocin plus kisspeptin
Study
ratn: not reported in source
Ovarian and uterine ischemia-reperfusion (I/R) injury
Comparator
Oxytocin plus kisspeptin
Outcome group
Organ injury · Reproductive and sexual health
Source sentences
Summary
There is no significant difference between OXY and OXY + Kisspeptin injected I/R groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Group 3, OXY administration 30 min prior to I/R applied rats; Group 4, Kisspeptin administration 30 min prior to I/R applied rats; Group 5, OXY and Kisspeptin administration 30 min prior to I/R.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2880560010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:04 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.